Brief: Geneuro’S Protect-MS Phase 2 Trial Data Confirms Synergistic Neuroprotective Potential Of Temelimab In MS
28/10/2022 06:32
Oct 28 (Reuters) - Geneuro Sa GNRO.PA :
* GENEURO’S PROTECT-MS PHASE 2 TRIAL DATA, PRESENTED AT THE
ECTRIMS 2022 CONGRESS IN AMSTERDAM, CONFIRMS SYNERGISTIC
NEUROPROTECTIVE POTENTIAL OF TEMELIMAB IN MS
* EXCELLENT SAFETY PROFILE AND TOLERABILITY OF HIGHER DOSES
OF
TEMELIMAB
Source text for Eikon: ID:nBwbSdQM8a
Further company coverage: GNRO.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Geneuro SA
See all newsBrief: Geneuro SA Postpones Publication Of Half-Yearly Financial Report
Brief: Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium
Brief: Geneuro SA Announces The Opening Of Receivership Proceedings For Its French Subsidiary Geneuro Innovation Sas
Brief: Geneuro Confirms Top-Line Results In Its Post-Covid Trial By End-June
Brief: Geneuro announces EUR 5 Mln private placement